IFLR1000

SinoMab BioScience HKSE IPO

12/11/2019
IPO
Select tab

HK$ 1.75 billion

Completed

12/11/2019

Overview:

  • Hong Kong-based biopharmacuetical company SinoMab BioScience has made a $223 million global offering and IPO on Hong Kong's stock exchange.
  • SinoMab BioScience is dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, primarily in monoclonal antibody-based biologics. 

Adam Majeed - Asia editor

Jurisdiction:

Hong Kong SAR

Deal type:

IPO

Practice area:

Capital markets : Equity

Industry sector:

Pharmaceuticals and life sciences

Firms:
Commerce & Finance Law Offices

Party: China International Capital Corporation Hong Kong Securities (Joint sponsor, Joint global coordinator, Joint lead manager, Joint bookrunner)

Party: Orient Securities (Joint global coordinator, Joint bookrunner, Joint lead manager)

Party: China Everbright Securities Ltd (Joint bookrunner, Joint lead manager)

Party: Guotai Junan Securities (Joint bookrunner, Joint lead manager)

Party: CMB International Capital (Joint bookrunner, Joint lead manager)

Party: Haitong International Securities Group Ltd (Joint bookrunner, Joint lead manager)

Party: Fosun Hani Securities (Joint bookrunner, Joint lead manager)

Party: Orient Capital (Joint sponsor)

Party: Victory Securities Company (Joint bookrunner, Joint lead manager)

Herbert Smith Freehills

Party: China International Capital Corporation Hong Kong Securities (Joint sponsor, Joint global coordinator, Joint bookrunner, Joint lead manager)

Party: Orient Securities (Joint global coordinator, Joint bookrunner, Joint lead manager)

Party: China Everbright Securities Ltd (Joint bookrunner, Joint lead manager)

Party: Guotai Junan Securities (Joint bookrunner, Joint lead manager)

Party: CMB International Capital (Joint bookrunner, Joint lead manager)

Party: Haitong International Securities Group Ltd (Joint bookrunner, Joint lead manager)

Party: Fosun Hani Securities (Joint bookrunner, Joint lead manager)

Party: Orient Capital (Joint sponsor)

Party: Victory Securities Company (Joint bookrunner, Joint lead manager)

Paul Hastings

Party: SinoMab BioScience (Issuer)

Zhong Lun Law Firm

Party: SinoMab BioScience (Issuer)

Lawyer: David Wang

Related deals